Inogen Is up Over 65% Since its IPO, Sees More Market Share Opportunity

4.5 million patients worldwide rely on supplemental oxygen therapy to treat their medical conditions. Co-Founder and CFO of Inogen, Alison Bauerlein, tells TheStreet's Jill Malandrino the impressive revenue numbers the company has driven is a result of the direct-to-consumer strategy and the awareness that it's bringing. The product itself is a life changer for patients because it gives them additional freedom and mobility that they don't get with a traditional tank-based model. Bauerlein explains Inogoen will continue on the direct approach with patients and doctors to continue on this momentum and that there is a significant opportunity to gain market share by penetrating the traditional treatment regimen.